CCF: Cleveland Clinic Foundation; ECOG PS: Eastern Cooperative Oncology Group Performance Score; IKCWG: International Kidney Cancer Working Group; MSKCC: Memorial Sloan–Kettering Cancer Center.
2013;13(6):697-709. In the pivotal Phase III trial of pazopanib, PFS was significantly prolonged by pazopanib treatment compared with placebo, regardless of MSKCC risk category. However ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback